Sex, gender, sexual orientation, and more: Sexual diversity in Alzheimer's research needs a new lens to achieve inclusive research and generalizable results

IF 4.9 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2024-06-24 DOI:10.1002/trc2.12476

Shana D. Stites, Beans Velocci

{"title":"Sex, gender, sexual orientation, and more: Sexual diversity in Alzheimer's research needs a new lens to achieve inclusive research and generalizable results","authors":"Shana D. Stites, Beans Velocci","doi":"10.1002/trc2.12476","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Diversity, Equity, and Inclusion (DEI) efforts in Alzheimer's disease and related dementia (ADRD) research are guiding the adoption of two-step self-report questions that capture research participants’ identity based on categories of sex, sexual orientation, and gender identity. The intent is to facilitate inclusion and representation of sexual and gender minoritized (SGM) communities in ADRD research. The data from using these questions are on a collision course with another National Institute of Aging initiative, which is aimed at understanding sex differences in ADRD mechanisms. Here, we critically analyze the goals and methods of the two initiatives. We propose that, in addition to being SGM focused, DEI efforts are needed to expand how scientists consider and measure sexual diversity itself.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Sex, sexual orientation, and gender identity (SSOGI) will be asked in ADRD studies.</li>\n \n <li>SSOGI data will expand representation of research participant identities.</li>\n \n <li>SSOGI data are on a collision course with sex differences research.</li>\n \n <li>Both emphasize sexual diversity (SD) largely as SSOGI identity categories.</li>\n \n <li>Diversity, Equity, and Inclusion efforts must develop SD methods in ADRD research.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"10 2","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11194612/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/trc2.12476","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Diversity, Equity, and Inclusion (DEI) efforts in Alzheimer's disease and related dementia (ADRD) research are guiding the adoption of two-step self-report questions that capture research participants’ identity based on categories of sex, sexual orientation, and gender identity. The intent is to facilitate inclusion and representation of sexual and gender minoritized (SGM) communities in ADRD research. The data from using these questions are on a collision course with another National Institute of Aging initiative, which is aimed at understanding sex differences in ADRD mechanisms. Here, we critically analyze the goals and methods of the two initiatives. We propose that, in addition to being SGM focused, DEI efforts are needed to expand how scientists consider and measure sexual diversity itself.

Highlights

Sex, sexual orientation, and gender identity (SSOGI) will be asked in ADRD studies.
SSOGI data will expand representation of research participant identities.
SSOGI data are on a collision course with sex differences research.
Both emphasize sexual diversity (SD) largely as SSOGI identity categories.
Diversity, Equity, and Inclusion efforts must develop SD methods in ADRD research.

查看原文本刊更多论文

性、性别、性取向等等：阿尔茨海默氏症研究中的性取向多样性需要一个新的视角，以实现包容性研究和可推广的结果。

阿尔茨海默病及相关痴呆症（ADRD）研究中的多样性、公平性和包容性（DEI）工作正在指导采用两步式自我报告问题，根据性别、性取向和性别认同类别捕捉研究参与者的身份。这样做的目的是为了促进在 ADRD 研究中纳入性和性别少数群体 (SGM) 并使其具有代表性。使用这些问题得出的数据与美国国家老龄化研究所的另一项旨在了解 ADRD 机制中性别差异的计划相冲突。在此，我们对这两项计划的目标和方法进行了批判性分析。我们建议，除了关注 SGM 外，DEI 的工作还需要扩大科学家考虑和衡量性别多样性本身的方式：性别、性取向和性别认同（SSOGI）将在 ADRD 研究中被问及。SSOGI 数据将扩大研究参与者身份的代表性。SSOGI 数据与性别差异研究相冲突。两者都强调性多样性（SD）主要是 SSOGI 身份类别。Diversity、Equity 和 Inclusion 工作必须在 ADRD 研究中开发 SD 方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.